Formulary updates effective Jan. 1, 2026

Dec. 2025Pharmacy Updates
Please be aware as of January 2026, there will be updates impacting formularies for all lines of business, coverage of adalimumab products, coverage of continuous glucose monitors (CGM), and billing processes for hyaluronate intra-articular injections and select intravenous and subcutaneous products. Please review the full details that include additional information on each change.

Recent Announcements

Medical device correction: FreeStyle Libre 3 (Abbott – December)

Abbott has announced a medical device correction for certain FreeStyle Libre 3 sensors. These sensors monitor blood glucose levels as part of the FreeStyle Libre system, which includes a sensor, reader, and app. The correction applies only to the sensor. No other Libre products or Abbott biowearables are affected.
Dec. 2025Pharmacy Updates

CME Webinar: The State of Telehealth in 2026

Please join us for a live, CME-accredited webinar on Tuesday, Jan. 27, from noon to 1 p.m. that will share updates on the state of telehealth for 2026.
Dec. 2025Education/Webinars

Voluntary nationwide recall: Famotidine (Fresenius – November)

Fresenius Kabi USA, LLC is recalling three lots (6133156, 6133194, and 6133388) of Famotidine Injection, USP, 20 mg per 2 mL. Famotidine is used to treat excessive secretion of stomach acid or stomach ulcers.
Nov. 2025Pharmacy Updates